Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | GBA1 | P04062 | 5/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868215 | 0.95 | PDE5A (0.82) | PDE5AMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL1085431 | 0.90 | PDE5A (1.00) | PDE5AMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL5138849 | 0.87 | PDE5A (0.82) | PDE5AMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL4867362 | 0.87 | PDE5A (0.82) | PDE5AMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL2591972 | 0.86 | PDE5A (1.00) | PDE5AMAPK1MEN1KMT2AGBA1 | |
| SCHEMBL5100868 | 0.86 | PDE5A (0.72) | PDE5AMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL4864232 | 0.86 | MEN1 (0.74) | PDE5AMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL4867641 | 0.86 | PDE5A (0.78) | PDE5AMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL4913681 | 0.84 | GBA1 (0.71) | PDE5AMAPK1KDM4EMEN1KMT2A | |
| SCHEMBL5113059 | 0.84 | PDE5A (0.64) | PDE5AMAPK1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | claimed |
| JP-2008526734-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | disclosed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | GPR119, GCKR, GLP1R | PDE5A 204/4885MAPK1 513/4885KDM4E 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.